Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of SUNPG1623

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has provided written informed consent~* Subject is ≥ 18 years of age at time of Screening~* Subject must be on stable dose of NSAID for ≥ 4 weeks prior to initiation of IMP~* Subject has a negative evaluation for TB within 4 weeks before initiating IMP~* Subject has a diagnosis of PsA (by the Classification of Psoriatic Arthritis \[CASPAR\] criteria) with symptoms present for at least 6 months.~* Subject has ≥ 3 tender and ≥ 3 swollen joints at Screening and Baseline.~Exclusion Criteria:~* Subject has a planned surgical intervention between Baseline and the Week 24 evaluation for a pretreatment condition~* Subject has an active infection or history of infections~* Subject has any concurrent medical condition or uncontrolled, clinically significant systemic disease~* Subject has a known history of infection with hepatitis B, hepatitis C, or human immunodeficiency virus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SUNPG1623 dose I (Type: EXPERIMENTAL): low range dose
- SUNPG1623 dose II (Type: EXPERIMENTAL): mid range dose
- SUNPG1623 dose III (Type: EXPERIMENTAL): mid range dose
- SUNPG1623 dose IV (Type: EXPERIMENTAL): mid range dose to high dose
- Placebo (Type: PLACEBO_COMPARATOR): mid range dose to high dose

Based on this trial design, predict the completion outcome and termination type (if applicable).